Business Wire

New Report From Arthur D. Little Highlights Full Potential of Artificial Intelligence for Business

2.12.2021 15:03:00 EET | Business Wire | Press release

Share

Arthur D. Little (ADL) has launched a new report which examines how artificial intelligence (AI) can be used to its full potential in the context of business decision making. The report – ‘From Insight to Impact’ looks at how companies can use AI more holistically rather than to just perform discrete functions and includes real world use cases where AI has demonstrated its ability to powerfully augment and improve business processes.

In a survey conducted for the report, only 16% of respondents believed that their organizations were benefitting from the full potential of AI technology. For the great majority, AI applications remain stuck at the pilot stage or are limited to just specific applications such as online customer interaction. The survey also showed that concerns still exist around the more widespread use of AI, with loss of control, lack of transparency, and the perceived threat of job losses all flagged as potential issues.

ADL’s report has been produced to cut through both the hype and negative connotations around AI. Based on in-depth, first-hand experience and primary research across multiple industries, the report provides practical, realistic insight into how additional business impact can be achieved via AI. It also proposes a clear approach that organizations can adopt in order to maximize the benefits of AI, including governance, setting up multidisciplinary teams, developing data frameworks, and implementing the right technology platforms.

The use cases the report cites include: predicting rail network disruptions; forecasting petrochemical prices; optimizing telecoms networks; managing pharmaceutical regulations; improving product development in the food industry; and making chemical plants more energy efficient.

Michael Kolk, Managing Partner at ADL and the Global Lead for the Technology & Innovation Management (TIM) practice, comments: “A crucial starting point for unlocking the full potential of AI within business is to establish its aim as being to augment, rather than replace, human decision making. Deployed properly, it is a way to help people make smarter, faster and more informed decisions that benefit the entire organization, not just small aspects of it. But to do this successfully requires a holistic strategy that goes far beyond simply employing data scientists and starting discrete pilot projects.”

The report is available here: www.adl.com/InsightToImpact

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Further information from:
Cate Bonthuys
Catalyst Comms
+44 7746 546773
cate@catalystcomms.co.uk

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release

Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary

MariaDB Launches into the Agentic Era with an Agent-Ready Platform and a Bold New Brand4.11.2026 15:00:00 EET | Press release

MariaDB plc, the Unified Open Database Platform for the Agentic Enterprise, today announced MariaDB Enterprise Platform 2027, a release that delivers 56% higher peak throughput¹, stronger resilience for multi-region deployments and faster ways to build and run AI agents. What began as an open source operational database now spans mission-critical transactions, real-time analytics, in-memory speed, AI tooling and multi-region scale on one unified platform. The new brand identity unveiled alongside it shows where the company is headed, powering the AI-driven enterprise with the world’s most trusted database platform. Every AI agent in production is betting that the data in front of it is true. In most enterprises, that data is spread across multiple operational databases, a warehouse, vector stores, ETL engines and caches, and every integration between them adds latency, sync lag and another point of failure. The pressure is about to multiply. IDC predicts that by 2027, G2000 [the world’

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye